Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva(R) Tablets

Launch further strengthens Mylan's leading antiretroviral portfolio Mylan is eligible for 180 days of exclusivity HERTFORDSHIRE, England and PITTSBURGH, Feb. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Global pharmaceutical leader Mylan N.V... Biopharmaceuticals, HIV/AIDS, Generics, Product Launch Mylan, Efavirenz, Sustiva
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news